Blog

Posts Tagged ‘biotech stocks’

Vaxart gives back yesterday’s gains from hamster study milestone

Shares of Vaxart (VXRT) closed down 10.04% today, October 14, giving back all of its 8.8% gain from Tuesday. The shares finished the October 14 session at $6.90. Yesterday, the company, which is working on a coronavirus vaccine in pill form, reported that hamsters who had received the vaccine showed no systemic weight loss. That is […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

My coronavirus vaccine pick Vaxart continues its recovery

Shares of Vaxart (VXRT) were up 21.77% today to $11.44 as of 3:15 p.m. New York time. You'll remember that Vaxart is my pick in my Volatility Portfolio for participating in the coronavirus vaccine race that plunged 47.6% from $16.97 on July 14 to to $8.90 a share on August 4 on a underreported (in […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Incyte beats on earnings, revenue–but drops on lack of improved guidance

Shares of biotech Incyte (INCY) were down 2.60% as of 1:30 p.m. Tuesday on earnings and revenue that stomped Wall Street projections. The company reported second quarter adjusted earnings of $1.24 a share versus Wall Street projections for 50 cents a share. Earnings are up from 75 cents a share in the second quarter of […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Analyst upgrade is catalyst for 6.17% jump in Acadia Pharmaceuticals today

 Stifel analyst Paul Matteis upgraded Acadia Pharmaceuticals (ACAD) to a Buy from a Hold today and raised his target price to $71 from $41. (Shares closed at $57 today, up 6.17%) The upgrade from Matteis was especially powerful since he has been skeptical on the stock and the potential for its primavanserin to win approval for […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

4th pick for Special Report 10 Stocks to Beat Amazon–SGEN

My fourth pick in my Special Report "10 Stocks to Beat Amazon" is a biotech, Seattle Genetics (SGEN). Biotech companies spend years developing their first successful drug. And then spend more years turning that first drug into a pipeline of drugs and expanded labels. The risk, of course, is that the drug development efforts won't […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Raising my target price on Incyte to $120 a share after 58.5% gain in last 3 months

I admit it. I feel silly talking about price targets and valuations in this market. After all everything is just going to the sky. Infinity and Beyond!!! But, as silly as I may feel, I don't think the gods of investing have repealed the laws of valuation. At some point--when, only the world's central bankers […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Trump administration picks five coronavirus vaccine efforts to receive big government funding

The Trump administration has identified five companies that will get major government funding for the development of a coronavirus vaccine under Operation Warp Speed, the New York Times reported yesterday. The White House is expected to officially announce the names of the five companies on the short list sometime in the next few weeks. The […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Stock Pick of the Day: Acadia Pharmaceuticals (ACAD)

As I wrote in my previous post this morning, I like the upward momentum in the biotech sector resulting from the race for a coronavirus vaccine and treatment and the cash flows into the sector from investors and big drug companies such as Pfizer (PFE.) That has pushed the iShares NASDAQ Biotechnology ETF (IBB) up […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

More headroom for biotech sector–and heads up on a coming pick

On May 29 the iShares NASDAQ Biotechnology ETF (IBB) hit an all-time high of $134.85, breaking the record of $133 set in 2015. Not surprising with money flooding into the sector as everyone and their Aunt Sally looks to find the stock that will rocket to the moon on the discovery of an coronavirus vaccine […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Still selling Intrexon (now Precigen) even though the 293% gain yesterday wasn’t real

Frankly, my first reaction was to think it was a misprint, especially because while the ticker still read XON, the name of the attached stock had changed from Intrexon to Precigen. And it was. A misprint, that is. The print yesterday showed that the stock, a member of my Volatility Portfolio since November 9, 2018, had […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.